The N6-methyladenosine:mechanisms, diagnostic value, immunotherapy prospec-ts and challenges in gastric cancer

The N6-methyladenosine (m6A) RNA modification is important in post-transcriptional regulation of RNA and are regulated reversibly by methyltransferases (writers), demethylases (erasers) and m6A recognition proteins (readers). Changes in the structure and function of key RNAs contribute to the develo...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Experimental cell research 2022-06, Vol.415 (2), p.113115-113115, Article 113115
Hauptverfasser: Wu, Wenzhang, Zhang, Fan, Zhao, Jun, He, Puyi, Li, Yumin
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 113115
container_issue 2
container_start_page 113115
container_title Experimental cell research
container_volume 415
creator Wu, Wenzhang
Zhang, Fan
Zhao, Jun
He, Puyi
Li, Yumin
description The N6-methyladenosine (m6A) RNA modification is important in post-transcriptional regulation of RNA and are regulated reversibly by methyltransferases (writers), demethylases (erasers) and m6A recognition proteins (readers). Changes in the structure and function of key RNAs contribute to the development of diseases, particularly tumors. Many abnormal expressions of molecules related to m6A RNA methylation modification are discovered in gastric cancer (GC), which changes the methylation level and stability of target genes after transcription, and then regulates related metabolic pathways, affecting the occurrence and progression of GC. Therefore, an in-depth study of m6A RNA modification in GC is conducive to the development of new tumor therapies and the achieve of individualized treatment. At present, both basic and clinical studies indicate that m6A plays a complex and contentious role in GC. In this paper, we not only review the roles and mechanisms of m6A modified related proteins, but also discuss the value of m6A modulators in the clinical applications and current challenges of GC, aiming to provide research clues for the early diagnosis and explore the feasibility of m6A related proteins as specific targets for GC immunotherapy.
doi_str_mv 10.1016/j.yexcr.2022.113115
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2644360758</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0014482722001082</els_id><sourcerecordid>2644360758</sourcerecordid><originalsourceid>FETCH-LOGICAL-c359t-e423abc77df91ddefc4bc3bbcbcbe07a8e5512b8caf1a81b563ebad036018a893</originalsourceid><addsrcrecordid>eNp9kE1r3DAQhkVpaLZpf0Gh6NhDvNVIsq0t9BBCvyAkl-QsxtJ4V4stbyU7dP99lW7aY9FhQDzvfDyMvQOxBgHNx_36SL9cWksh5RpAAdQv2ArERlRSS_mSrYQAXWkj23P2Oue9EMIYaF6xc1UrDW2rVyze74jfNtVI8-44oKc45RDp00huhzHkMV9yH3Bbvufg-CMOC13yMI5LnOYdJTwc-SFN-UCumjPH6HkJDgPFLWUeIt9inlNJOoyO0ht21uOQ6e1zvWAPX7_cX3-vbu6-_bi-uqmcqjdzRVoq7Fzb-n4D3lPvdOdU17nySLRoqK5BdsZhD2igqxtFHXqhGgEGzUZdsA-nvmW3nwvl2Y4hOxoGjDQt2cpG6wK3tSmoOqGunJET9faQwojpaEHYJ9F2b_-Itk-i7Ul0Sb1_HrB0I_l_mb9mC_D5BFA58zFQstkFKg58SORm66fw3wG_AXoxkvs</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2644360758</pqid></control><display><type>article</type><title>The N6-methyladenosine:mechanisms, diagnostic value, immunotherapy prospec-ts and challenges in gastric cancer</title><source>Access via ScienceDirect (Elsevier)</source><creator>Wu, Wenzhang ; Zhang, Fan ; Zhao, Jun ; He, Puyi ; Li, Yumin</creator><creatorcontrib>Wu, Wenzhang ; Zhang, Fan ; Zhao, Jun ; He, Puyi ; Li, Yumin</creatorcontrib><description>The N6-methyladenosine (m6A) RNA modification is important in post-transcriptional regulation of RNA and are regulated reversibly by methyltransferases (writers), demethylases (erasers) and m6A recognition proteins (readers). Changes in the structure and function of key RNAs contribute to the development of diseases, particularly tumors. Many abnormal expressions of molecules related to m6A RNA methylation modification are discovered in gastric cancer (GC), which changes the methylation level and stability of target genes after transcription, and then regulates related metabolic pathways, affecting the occurrence and progression of GC. Therefore, an in-depth study of m6A RNA modification in GC is conducive to the development of new tumor therapies and the achieve of individualized treatment. At present, both basic and clinical studies indicate that m6A plays a complex and contentious role in GC. In this paper, we not only review the roles and mechanisms of m6A modified related proteins, but also discuss the value of m6A modulators in the clinical applications and current challenges of GC, aiming to provide research clues for the early diagnosis and explore the feasibility of m6A related proteins as specific targets for GC immunotherapy.</description><identifier>ISSN: 0014-4827</identifier><identifier>EISSN: 1090-2422</identifier><identifier>DOI: 10.1016/j.yexcr.2022.113115</identifier><identifier>PMID: 35341774</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Epitranscriptome ; Gastric cancer ; Immunotherapy ; m6A ; Post-transcriptional ; RNA methylation</subject><ispartof>Experimental cell research, 2022-06, Vol.415 (2), p.113115-113115, Article 113115</ispartof><rights>2022</rights><rights>Copyright © 2022. Published by Elsevier Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c359t-e423abc77df91ddefc4bc3bbcbcbe07a8e5512b8caf1a81b563ebad036018a893</citedby><cites>FETCH-LOGICAL-c359t-e423abc77df91ddefc4bc3bbcbcbe07a8e5512b8caf1a81b563ebad036018a893</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.yexcr.2022.113115$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35341774$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wu, Wenzhang</creatorcontrib><creatorcontrib>Zhang, Fan</creatorcontrib><creatorcontrib>Zhao, Jun</creatorcontrib><creatorcontrib>He, Puyi</creatorcontrib><creatorcontrib>Li, Yumin</creatorcontrib><title>The N6-methyladenosine:mechanisms, diagnostic value, immunotherapy prospec-ts and challenges in gastric cancer</title><title>Experimental cell research</title><addtitle>Exp Cell Res</addtitle><description>The N6-methyladenosine (m6A) RNA modification is important in post-transcriptional regulation of RNA and are regulated reversibly by methyltransferases (writers), demethylases (erasers) and m6A recognition proteins (readers). Changes in the structure and function of key RNAs contribute to the development of diseases, particularly tumors. Many abnormal expressions of molecules related to m6A RNA methylation modification are discovered in gastric cancer (GC), which changes the methylation level and stability of target genes after transcription, and then regulates related metabolic pathways, affecting the occurrence and progression of GC. Therefore, an in-depth study of m6A RNA modification in GC is conducive to the development of new tumor therapies and the achieve of individualized treatment. At present, both basic and clinical studies indicate that m6A plays a complex and contentious role in GC. In this paper, we not only review the roles and mechanisms of m6A modified related proteins, but also discuss the value of m6A modulators in the clinical applications and current challenges of GC, aiming to provide research clues for the early diagnosis and explore the feasibility of m6A related proteins as specific targets for GC immunotherapy.</description><subject>Epitranscriptome</subject><subject>Gastric cancer</subject><subject>Immunotherapy</subject><subject>m6A</subject><subject>Post-transcriptional</subject><subject>RNA methylation</subject><issn>0014-4827</issn><issn>1090-2422</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNp9kE1r3DAQhkVpaLZpf0Gh6NhDvNVIsq0t9BBCvyAkl-QsxtJ4V4stbyU7dP99lW7aY9FhQDzvfDyMvQOxBgHNx_36SL9cWksh5RpAAdQv2ArERlRSS_mSrYQAXWkj23P2Oue9EMIYaF6xc1UrDW2rVyze74jfNtVI8-44oKc45RDp00huhzHkMV9yH3Bbvufg-CMOC13yMI5LnOYdJTwc-SFN-UCumjPH6HkJDgPFLWUeIt9inlNJOoyO0ht21uOQ6e1zvWAPX7_cX3-vbu6-_bi-uqmcqjdzRVoq7Fzb-n4D3lPvdOdU17nySLRoqK5BdsZhD2igqxtFHXqhGgEGzUZdsA-nvmW3nwvl2Y4hOxoGjDQt2cpG6wK3tSmoOqGunJET9faQwojpaEHYJ9F2b_-Itk-i7Ul0Sb1_HrB0I_l_mb9mC_D5BFA58zFQstkFKg58SORm66fw3wG_AXoxkvs</recordid><startdate>20220615</startdate><enddate>20220615</enddate><creator>Wu, Wenzhang</creator><creator>Zhang, Fan</creator><creator>Zhao, Jun</creator><creator>He, Puyi</creator><creator>Li, Yumin</creator><general>Elsevier Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20220615</creationdate><title>The N6-methyladenosine:mechanisms, diagnostic value, immunotherapy prospec-ts and challenges in gastric cancer</title><author>Wu, Wenzhang ; Zhang, Fan ; Zhao, Jun ; He, Puyi ; Li, Yumin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c359t-e423abc77df91ddefc4bc3bbcbcbe07a8e5512b8caf1a81b563ebad036018a893</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Epitranscriptome</topic><topic>Gastric cancer</topic><topic>Immunotherapy</topic><topic>m6A</topic><topic>Post-transcriptional</topic><topic>RNA methylation</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wu, Wenzhang</creatorcontrib><creatorcontrib>Zhang, Fan</creatorcontrib><creatorcontrib>Zhao, Jun</creatorcontrib><creatorcontrib>He, Puyi</creatorcontrib><creatorcontrib>Li, Yumin</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Experimental cell research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wu, Wenzhang</au><au>Zhang, Fan</au><au>Zhao, Jun</au><au>He, Puyi</au><au>Li, Yumin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The N6-methyladenosine:mechanisms, diagnostic value, immunotherapy prospec-ts and challenges in gastric cancer</atitle><jtitle>Experimental cell research</jtitle><addtitle>Exp Cell Res</addtitle><date>2022-06-15</date><risdate>2022</risdate><volume>415</volume><issue>2</issue><spage>113115</spage><epage>113115</epage><pages>113115-113115</pages><artnum>113115</artnum><issn>0014-4827</issn><eissn>1090-2422</eissn><abstract>The N6-methyladenosine (m6A) RNA modification is important in post-transcriptional regulation of RNA and are regulated reversibly by methyltransferases (writers), demethylases (erasers) and m6A recognition proteins (readers). Changes in the structure and function of key RNAs contribute to the development of diseases, particularly tumors. Many abnormal expressions of molecules related to m6A RNA methylation modification are discovered in gastric cancer (GC), which changes the methylation level and stability of target genes after transcription, and then regulates related metabolic pathways, affecting the occurrence and progression of GC. Therefore, an in-depth study of m6A RNA modification in GC is conducive to the development of new tumor therapies and the achieve of individualized treatment. At present, both basic and clinical studies indicate that m6A plays a complex and contentious role in GC. In this paper, we not only review the roles and mechanisms of m6A modified related proteins, but also discuss the value of m6A modulators in the clinical applications and current challenges of GC, aiming to provide research clues for the early diagnosis and explore the feasibility of m6A related proteins as specific targets for GC immunotherapy.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>35341774</pmid><doi>10.1016/j.yexcr.2022.113115</doi><tpages>1</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0014-4827
ispartof Experimental cell research, 2022-06, Vol.415 (2), p.113115-113115, Article 113115
issn 0014-4827
1090-2422
language eng
recordid cdi_proquest_miscellaneous_2644360758
source Access via ScienceDirect (Elsevier)
subjects Epitranscriptome
Gastric cancer
Immunotherapy
m6A
Post-transcriptional
RNA methylation
title The N6-methyladenosine:mechanisms, diagnostic value, immunotherapy prospec-ts and challenges in gastric cancer
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T06%3A16%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20N6-methyladenosine:mechanisms,%20diagnostic%20value,%20immunotherapy%20prospec-ts%20and%20challenges%20in%20gastric%20cancer&rft.jtitle=Experimental%20cell%20research&rft.au=Wu,%20Wenzhang&rft.date=2022-06-15&rft.volume=415&rft.issue=2&rft.spage=113115&rft.epage=113115&rft.pages=113115-113115&rft.artnum=113115&rft.issn=0014-4827&rft.eissn=1090-2422&rft_id=info:doi/10.1016/j.yexcr.2022.113115&rft_dat=%3Cproquest_cross%3E2644360758%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2644360758&rft_id=info:pmid/35341774&rft_els_id=S0014482722001082&rfr_iscdi=true